Background and Purpose-Transient or permanent neurological deficits can occur in the periprocedural period following carotid angioplasty and stenting (CAS), presumably due to distal embolization and/or hemodynamic compromise. We performed this study to identify predictors of neurological deficits associated with carotid angioplasty and stent placement. Methods-We reviewed medical records and angiograms in a consecutive series of patients who underwent CAS for symptomatic or asymptomatic cervical internal carotid artery stenosis from June 1996 through December 1998. Using logistic regression analysis, we evaluated the effect of demographic, clinical, intraprocedural, and angiographic risk factors on subsequent development of periprocedural neurological deficits. Periprocedural neurological deficits were defined as new or worsening transient or permanent neurological deficits that occurred during or within 48 hours of the procedure. Results-A total of 111 patients (mean age 68.2Ϯ9.1 years) who underwent CAS for asymptomatic (nϭ54) or symptomatic (nϭ57) stenoses were included in this study. A total of 14 periprocedural neurological deficits (13%) were observed either during (nϭ4) or after (nϭ10) the procedure. Three identified variables were independently associated with periprocedural neurological deficits: symptomatic lesion (OR 8.3, 95% CI 1.6 to 42.6), length of stenotic segment Ն11.2 mm (OR 5.2, 95% CI 1.2 to 22.5), and absence of hypercholesterolemia (OR 5.4, 95% CI 1.4 to 20.9). Other variables, including age and degree of stenosis (defined by NASCET criteria), were not associated with periprocedural neurological deficits. Conclusions-A combination of clinical and angiographic variables can be used to identify patients at risk for periprocedural neurological deficits after CAS. Such identification may help in selection of patients who may benefit from novel pharmacological and mechanical preventive approaches. (Stroke. 2000;31:376-382.)
R ecently, carotid angioplasty and stenting (CAS) has been introduced as an alternative to carotid endarterectomy (CEA) for treatment of carotid stenosis. [1] [2] [3] [4] Temporary or permanent neurological deficits can occur during and after carotid angioplasty and stent placement. The frequency of neurological deficits has ranged from 3% to 13% in previous reports. 4 -8 Almost all of these events are ischemic in origin and related to distal embolization and/or hemodynamic compromise. Novel pharmacological 9 -13 and mechanical approaches 14, 15 are being introduced as adjuncts to angioplasty and stent placement to reduce the risk of these events. An important issue that needs to be addressed is the identification of patients who are at highest risk for neurological events and therefore will benefit most from use of these new preventive approaches and strategies. We performed this study to identify patients at risk for neurological events associated with carotid angioplasty and stent placement using routinely available data in a consecutive series of patients.
Subjects and Methods

Patients
We reviewed the medical records of all patients who underwent carotid artery angioplasty and stent placement from June 1996 through December 1998. Our institution's Human Investigations Committee approved the study. Patients were identified by a local registry maintained by the Department of Neurosurgery. Only patients who underwent angioplasty for cervical internal carotid artery stenosis with or without extension into bifurcation and common carotid artery were included. Patients were excluded if they had stenosis related to dissection or radiation therapy.
Of 220 cases at our institution since 1995, only the most recent 120 cases performed between June 1996 and December 1998 were included, because the angiographic images were available in digital form on video tape, which allowed adequate characterization of lesion morphology.
Protocol for Angioplasty and Stent Placement
Patients were started 72 hours before the procedure on aspirin 325 mg/d, and ticlopidine 250 mg twice daily or clopidogrel 75 mg/d. On the day of the procedure, each patient was evaluated by one of the physicians from the endovascular team, and a complete physical and neurological examination was documented. Each patient was given 10 mg of decadron and 60 mg of nimodipine orally on the morning of the procedure. All the procedures were performed under local anesthesia. A baseline angiogram was performed, and the lumen diameter of the stenotic and adjacent segments were measured. An intravenous heparin bolus 5000 to 7500 U was given to achieve activated thromboplastin time between 300 and 350 seconds. Before introduction of the balloon, intra-arterial urokinase 100 000 to 250 000 U was infused locally through a microcatheter if there was any subjective evidence of local thrombosis or ulceration in the stenotic segment on magnified biplane angiography. 16 It should be noted that the decision to use urokinase was subject to treating physician's preference and angiographic interpretation. Either a 9F catheter or a 7F guide sheath was advanced into the common carotid artery and placed proximal to the stenosis. The flexible guidewire (0.14 to 0.18 inches in diameter) with angulated tip was advanced through the guide catheter, navigated across the stenosis, and positioned in the distal arterial segment. The vessel was predilated with a percutaneous transluminal angioplasty balloon (PTA) catheter placed across the stenosis. The objective of the predilatation was to dilate the vessel just enough to allow safe passage of the stent delivery device. After predilatation, a stent was placed across the dilated segment over the guidewire with a stent delivery system. The size of stent selected was determined by evaluation and measurement of both baseline and postdilatation angiographic studies. The type of stent was chosen according to physician preference, lesion characteristics, and commercial availability. A poststent dilatation of the angioplasty balloon was performed to fully expand the stent to reference diameter. When the inflation had been completed, a final cervical and intracranial angiogram was obtained to confirm that the result was satisfactory and that intracranial circulation had not been compromised. Limited neurological examinations were performed throughout the procedure, and a complete examination was documented at completion.
The patient was transferred to the neurointensive care unit for overnight observation. Heart and respiratory rates were continuously monitored. Blood pressure was monitored every 15 minutes. Three complete neurological examinations were documented by physicians for each patient. The first evaluation was performed before the procedure. Subsequent evaluations were performed immediately and 24 hours after the procedure. Neurological evaluations were performed every 2 hours and more frequently if necessary by the nurses in the neurointensive care unit. Any episode of neurological change detected during the nurses' examination was further evaluated by a physician.
Data Collection
Medical records were reviewed, and the following information was collected for each patient: age and sex; current smoking or alcohol use; known angina pectoralis, previous myocardial infarction (MI), coronary artery disease, hypertension, diabetes mellitus, hypercholesterolemia (defined as serum cholesterol Ͼ200 mg/dL or use of antilipidemic medications), cardiac dysrhythmias, valvular heart disease, cardiac failure, peripheral vascular disease, or renal insufficiency; history of previous coronary bypass or angioplasty or carotid endarterectomy; and use of antiplatelet or other medications before admission. Any clinical symptoms were noted and used to evaluate whether ipsilateral or contralateral carotid artery was symptomatic. The following details were collected for the procedure: the size and number of balloon inflations and the size and type of stent placed. We also recorded any new or worsening neurological deficits during or within 48 hours of the procedure. The total period of intensive care unit and hospital stay was recorded. Any nonneurological complications during hospitalization were noted.
Evaluation of Angiograms
Digital subtraction angiographic images were retrospectively collected from the digital tape storage system of our angiography unit (Toshiba Inc). Ipsilateral and contralateral diagnostic images of the extracranial carotid arteries and the intracranial circulation were obtained, as well as images of the stented artery and of the intracranial perfusion after stent placement. The images of extracranial carotid arteries were transferred to a computer workstation running NIH Image software (http://rsb.info.nih.gov/NIH-IMAGE/) for subsequent measurements. One of the investigators, who was blinded to the clinical data and outcome of the patients, performed all the measurements. After adjusting for magnification, the diameters of the stenosis, of the distal internal carotid artery, and of the stented lesion were measured. The degree of stenosis was calculated according to the NASCET method, ie, 1Ϫ(diameter of stenosis/distal ICA diameter). This method was chosen to ensure comparability with other studies. 17 The extension of the lesion was classified whether it was limited to the internal carotid artery or extended into the common carotid artery. The length of the lesion was measured, and each lesion was classified morphologically as regular, irregular, or irregular and ulcerated. Each of these morphological features was further analyzed as a dichotomized variable (smooth versus irregular with or without ulceration).
Statistical Analysis
The effects of 21 variables collected from archived patient charts and 6 variables obtained from angiographic images were evaluated on periprocedural neurological deficits, which were defined as new or worsening neurological deficits during or within 48 hours after carotid angioplasty and stent placement. The association between continuous variables and neurological deficits was plotted to test for linearity of the relation as suggested by Hosmer and Lemeshow. 18 Age was found to have a linear relationship and thus included as a continuous variable. For degree of stenosis and lesion length, a nonlinear relationship was observed. According to the "shape" of the curve, the continuous variable "degree of stenosis" was divided into 4 groups: Յ55%, 56% through 68%, 69% through 75%, and Ͼ75%. Lesion length was dichotomized at 11.2 mm and then entered in the multivariate model. Systat (Version 8, SPSS Inc) statistical software was used for all analyses. All collected variables were initially entered into the logistic regression model on "neurological complication" as the dependent variable. Backward stepwise exclusion of variables was performed using a criterion of PϾ0.1. After a set of significant variables were identified, possible interactions were added to the model and retested with backward stepwise regression. All interactions were nonsignificant and did not remain in the model.
Results
A total of 120 patients underwent carotid angioplasty and stent placement from July 1996 through December 1998. Nine patients were excluded because either complete clinical (nϭ7) or angiographic (nϭ2) material was not available. A total of 111 patients (mean age 68.2Ϯ9.1 years) undergoing CAS for asymptomatic (nϭ54) or symptomatic stenosis (nϭ57) were included in the study. The frequency of periprocedural neurological deficits was similar in the excluded patients (1 of 9 patients) compared with the included patients Periprocedural neurological deficits occurred in 14 patients (13%) either during (nϭ4) or after (nϭ10) the procedure. Eight of 14 events occurred in the first 24 hours after the procedure, and another 2 occurred at 48 hours after the procedure. New deficits were observed in 12 patients, and 2 patients experienced worsening of preexisting deficits. Neurological deficits were referable to the hemisphere ipsilateral to the operated side in 11 patients. In the other 3 patients, neurological deficits were referable to the contralateral side. One patient had total occlusion of the carotid artery contralateral to the operated side. Another patient had high-grade carotid stenosis on the contralateral side and suffered deficits following an episode of hypotension in the postoperative period. The third patient had a previous stroke on the contralateral side and experience worsening of preexisting deficits in the postprocedural period. The deficits had resolved within 48 hours in 10 patients. At discharge, 1 patient had worsened left hemiparesis, 1 had moderate expressive aphasia with impaired fine finger movements, and the other 2 patients had mild residual weakness during hand movements. At 1-month follow-up, the deficits in 2 patients had improved. None of the new strokes was considered disabling. One patient had previous disability due to stroke that was unaffected by postprocedural worsening. Table 2 shows the demographic and clinical characteristics of the patients in the study. Prophylactic intra-arterial urokinase was administered before angioplasty in doses ranging from 100 000 IU to 250 000 IU. The frequency of periprocedural neurological deficits was similar in patients who received prophylactic urokinase (11 of 93) and those who did not (3 of 19, Pϭ0.6). Table 3 Table 4 ). Other variables, including age, sex, hypertension, diabetes, and smoking, did not increase the risk for neurological complications after angioplasty and stenting. The degree of stenosis (defined by NASCET criteria) was unrelated to periprocedural complications. 
Discussion Salient Findings of the Study
We identified 3 risk factors for periprocedural neurological deficits from a analysis of a consecutive series of patients who underwent carotid angioplasty and stent placement.
These factors were presence of symptomatic ipsilateral carotid artery stenosis, long stenotic lesions (defined as Ն11.2 mm in this study), and absence of hypercholesterolemia. Our study also points out the diverse nature of postoperative neurological deficits. Most neurological deficits (8 of 14 events) occurred in the first 24 hours after the procedure. Four events were observed during the procedure, and 2 others occurred at 48 hours after the procedure. The outcome of these events was favorable, with complete resolution observed within 48 hours in 10 of 14 patients.
Risk of Periprocedural Neurological Deficits
Previous studies have documented the risk of thromboembolic events associated with PTA alone or with stent placement. The risk of neurological events associated with PTA alone varies from 0% to 9%, depending on the patient population and procedural technique. 5,14,19 -21 Theron et al 14 reported 5 neurological events, related to either embolism or dissection, in 38 patients with asymptomatic carotid artery stenosis who underwent PTA. Gil-Peralta et al 5 reported 7 neurological events, related to either embolism or dissection, in a series of 82 patients who underwent PTA. The frequency of neurological events in patients who undergo PTA followed by stent placement ranges from 3% to 13%. 4,6 -8,20 Mathur et al 8 observed 19 neurological events in 231 patients who underwent PTA followed by stent placement. All events were related to thromboembolism. Henry et al 6 reported 8 neurological events among 163 patients who underwent PTA followed by stent placement. Jordan et al 7 observed 14 neurological events in a series of 107 patients who underwent PTA followed by stent placement. In our series, we observed a rate of 13% for periprocedural neurological deficits with the inclusion of transient events.
Risk Factors for Periprocedural Neurological Deficits
In our study, we identified 3 variables from numerous clinical and angiographic characteristics that identified patients at risk for the development of periprocedural neurological deficits. These included symptomatic lesion, absence of hypercholesterolemia, and lesion length by angiographic measurements. The intrinsic characteristics of the stenotic plaque observed in symptomatic patients predispose them to a higher risk of thromboembolic events. 22, 23 This is supported by the higher risk of periprocedural stroke observed during endarterectomy in symptomatic patients in NASCET and other studies compared with asymptomatic patients in the ACAS study. 24 -26 The plaque in symptomatic patients have a higher frequency of fissuring as well as in situ thrombosis. 22, 23 Both of these characteristics possibly contribute to increased thrombogenicity of the stenotic segment during and after PTA and stent placement. The relationship between periprocedural neurological deficits and absence of hypercholesterolemia is less obvious. The plaques in patients without hypercholesterolemia have a low content of lipid containing foam cells and glycosaminoglycan deposition. 27 Although most of our patients had carotid Doppler ultrasound performed, the studies were performed at different institutions and most reports provided only velocity measurements. Therefore, no comments can be made regarding the composition of plaque and its association with hypercholesterolemia in our series. Whether morphological characteristics of the plaque or undefined covariates in patients who develop carotid stenosis without hypercholesterolemia are responsible for this paradoxical association needs to be defined in future studies. The length of the lesion is another factor that determines the operative manipulation required and therefore the risk of complications. Longer lesions require longer stents and at times multiple angioplasties after stent placement to ensure adequate dilation across the stenosis. The postdilatation surface of longer lesions provides a larger area of endothelial injury, dissections, and stent struts that acts as a prothrombotic surface in the acute period after PTA and stent placement. 
Previous Study for Identification of Risk Factors
In a previous study, Mathur and coworkers 8 identified predictors of stroke in patients undergoing PTA followed by stent placement. Age, degree of stenosis, and the length or multiplicity of the lesions determined the stroke risk. Dependency on the degree of the stenosis was not linear. Stenosis of 70% to 80% posed the greatest risk, whereas greater or lesser stenoses were associated with fewer strokes. In our study, length of lesion was observed to be associated with periprocedural neurological deficits. Neither age nor degree of stenosis contributed to the risk of neurological events in our study. The outcome studied by Mathur et al 8 was stroke within 1 month of PTA and stent placement. In contrast, the outcome evaluated in our study consisted of neurological events within the first 48 hours after PTA and stent placement.
Potential Applications of the Predictive Scheme
We think that variables which are routinely available may be helpful in identification of those patients who may benefit most from novel approaches for prophylaxis of thromboembolic events. Multiple strategies are in practice to reduce the frequency of neurological events associated with PTA followed by stent placement. At present, the most common regimen consists of preoperative and postoperative use of aspirin with either ticlopidine or clopidogrel, and intravenous heparin to prolong activated thromboplastin time during the procedure. In our study and most of the previously mentioned studies, both antiplatelet medication and intraprocedural heparin were used. Novel preventive strategies, which include both pharmacological and mechanical approaches, are undergoing evaluation at present. These include the development of new antiplatelet medication, such as antibodies to platelet glycoprotein IIb/IIIa receptors. 9 -13 This is also supplemented by improvement in stent design and delivery devices. The high-risk group identified in our study may represent the best candidates for such approaches.
Generalizability of the Scheme
An issue related to interpretation of our results is whether the results are representative of PTA followed by stent placement in other institutions. At our institution, PTA followed by stent placement is generally reserved for patients who are poor candidates for carotid endarterectomy, as is evident by the high frequency of cardiac and other diseases observed in our patient population. Decadron used to be administered preoperatively at our institute, a practice which has been discontinued. The antiplatelet and heparin regimens we use are similar to those in other institutions that perform PTA and stent placement. Based on these observations, we think that these results can be used in other patient population as well.
We have used intra-arterial urokinase in a subset of patients 16 to dissolve loose intramural thrombi. In post hoc analysis, however, the use of intra-arterial urokinase did not influence the risk of neurological events. Prophylactic urokinase is no longer being used at our institution due to availability of more effective medications, such as glycoprotein IIb/IIIa inhibitors.
Limitations of the Study
Because of the retrospective nature of the study, we could not control for the exact frequency and extent of neurological examinations. This may induce an unrecognized bias. However, because the same physicians were involved in the care of all patients, little variability in practice patterns is expected. We were unable to validate the predictive value of the identified variables in a separate set of patients owing to the small number of subjects and observed events in this study.
Conclusions
A combination of clinical and laboratory variables can be used to identify patients at risk for periprocedural neurological deficits. Such identification may help in the selection of appropriate patients who are good candidates for novel pharmacological and mechanical preventive approaches. Prospective studies are required to validate the predictive significance of the identified variables.
